Seek Returns logo

LLY vs. RDDT: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at LLY and RDDT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolLLYRDDT
Company NameEli Lilly and CompanyReddit, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareCommunication Services
GICS IndustryPharmaceuticalsInteractive Media & Services
Market Capitalization758.15 billion USD37.86 billion USD
ExchangeNYSENYSE
Listing DateJune 1, 1972March 21, 2024
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of LLY and RDDT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

LLY vs. RDDT: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolLLYRDDT
5-Day Price Return3.16%0.68%
13-Week Price Return7.47%38.89%
26-Week Price Return7.18%108.76%
52-Week Price Return-5.86%187.18%
Month-to-Date Return10.84%-12.04%
Year-to-Date Return9.55%23.77%
10-Day Avg. Volume4.62M6.39M
3-Month Avg. Volume4.20M7.12M
3-Month Volatility45.12%65.58%
Beta0.372.11

Profitability

Return on Equity (TTM)

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

RDDT

9.93%

Interactive Media & Services Industry

Max
49.37%
Q3
33.08%
Median
10.37%
Q1
5.76%
Min
-24.17%

RDDT’s Return on Equity of 9.93% is on par with the norm for the Interactive Media & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY vs. RDDT: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Net Profit Margin (TTM)

LLY

25.91%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RDDT

12.97%

Interactive Media & Services Industry

Max
49.74%
Q3
29.54%
Median
20.53%
Q1
7.52%
Min
-14.52%

RDDT’s Net Profit Margin of 12.97% is aligned with the median group of its peers in the Interactive Media & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

LLY vs. RDDT: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Operating Profit Margin (TTM)

LLY

32.37%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RDDT

7.87%

Interactive Media & Services Industry

Max
65.96%
Q3
36.82%
Median
18.53%
Q1
7.69%
Min
-18.13%

RDDT’s Operating Profit Margin of 7.87% is around the midpoint for the Interactive Media & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

LLY vs. RDDT: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Profitability at a Glance

SymbolLLYRDDT
Return on Equity (TTM)88.36%9.93%
Return on Assets (TTM)16.02%9.04%
Net Profit Margin (TTM)25.91%12.97%
Operating Profit Margin (TTM)32.37%7.87%
Gross Profit Margin (TTM)82.64%91.04%

Financial Strength

Current Ratio (MRQ)

LLY

1.28

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

RDDT

12.00

Interactive Media & Services Industry

Max
3.92
Q3
2.72
Median
1.85
Q1
1.20
Min
0.25

RDDT’s Current Ratio of 12.00 is exceptionally high, placing it well outside the typical range for the Interactive Media & Services industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

LLY vs. RDDT: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

LLY

2.18

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

With a Debt-to-Equity Ratio of 2.18, LLY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

RDDT

0.00

Interactive Media & Services Industry

Max
0.85
Q3
0.49
Median
0.29
Q1
0.04
Min
0.00

Falling into the lower quartile for the Interactive Media & Services industry, RDDT’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

LLY vs. RDDT: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Interest Coverage Ratio (TTM)

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RDDT

--

Interactive Media & Services Industry

Max
23.65
Q3
16.48
Median
6.73
Q1
-0.87
Min
-3.62

Interest Coverage Ratio data for RDDT is currently unavailable.

LLY vs. RDDT: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Financial Strength at a Glance

SymbolLLYRDDT
Current Ratio (MRQ)1.2812.00
Quick Ratio (MRQ)0.5311.89
Debt-to-Equity Ratio (MRQ)2.180.00
Interest Coverage Ratio (TTM)20.36--

Growth

Revenue Growth

LLY vs. RDDT: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

LLY vs. RDDT: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

LLY

0.63%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

LLY’s Dividend Yield of 0.63% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RDDT

0.00%

Interactive Media & Services Industry

Max
3.07%
Q3
1.27%
Median
0.28%
Q1
0.00%
Min
0.00%

RDDT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

LLY vs. RDDT: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Dividend Payout Ratio (TTM)

LLY

36.46%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RDDT

0.00%

Interactive Media & Services Industry

Max
101.53%
Q3
40.64%
Median
0.00%
Q1
0.00%
Min
0.00%

RDDT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

LLY vs. RDDT: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Dividend at a Glance

SymbolLLYRDDT
Dividend Yield (TTM)0.63%0.00%
Dividend Payout Ratio (TTM)36.46%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

LLY

58.27

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

At 58.27, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

RDDT

175.00

Interactive Media & Services Industry

Max
50.72
Q3
41.60
Median
25.84
Q1
18.18
Min
1.76

At 175.00, RDDT’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Interactive Media & Services industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

LLY vs. RDDT: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

LLY

15.10

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

With a P/S Ratio of 15.10, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

RDDT

22.70

Interactive Media & Services Industry

Max
23.76
Q3
11.40
Median
7.69
Q1
2.49
Min
0.00

RDDT’s P/S Ratio of 22.70 is in the upper echelon for the Interactive Media & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

LLY vs. RDDT: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RDDT

11.64

Interactive Media & Services Industry

Max
16.71
Q3
9.00
Median
3.97
Q1
2.19
Min
0.33

RDDT’s P/B Ratio of 11.64 is in the upper tier for the Interactive Media & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

LLY vs. RDDT: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Interactive Media & Services industry benchmarks.

Valuation at a Glance

SymbolLLYRDDT
Price-to-Earnings Ratio (TTM)58.27175.00
Price-to-Sales Ratio (TTM)15.1022.70
Price-to-Book Ratio (MRQ)40.4311.64
Price-to-Free Cash Flow Ratio (TTM)400.1795.40